Sep 13, 2022 / 03:10PM GMT
Jeff Hung - Morgan Stanley, Research Division - Equity Analyst
Good morning, and welcome to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. For this session, we have ACADIA Pharmaceuticals with CEO, Steve Davis; and CFO, Mark Schneyer. Welcome, Steve, Mark.
Stephen R. Davis - ACADIA Pharmaceuticals Inc. - CEO & Director
Thank you.
Mark C. Schneyer - ACADIA Pharmaceuticals Inc. - Executive VP & CFO
Thanks, Jeff.
Questions and Answers:
Jeff Hung - Morgan Stanley, Research Division - Equity AnalystSo maybe let's start with NUPLAZID in PDP. With 2Q earnings, you reduced the top end of your net sales guidance range.